Symbol="FATE"
AssetType="Common Stock"
Name="Fate Therapeutics Inc"
Description="Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California."
CIK="1434316"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="273509000"
EBITDA="-225275008"
PERatio="None"
PEGRatio="0"
BookValue="4.443"
DividendPerShare="0"
DividendYield="0"
EPS="-2.4"
RevenuePerShareTTM="1.221"
ProfitMargin="-1.774"
OperatingMarginTTM="-2.029"
ReturnOnAssetsTTM="-0.217"
ReturnOnEquityTTM="-0.415"
RevenueTTM="119250000"
GrossProfitTTM="-224154000"
DilutedEPSTTM="-2.4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.95"
AnalystTargetPrice="7.24"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="20.01"
PriceToBookRatio="2.883"
EVToRevenue="15.93"
EVToEBITDA="-3.697"
Beta="1.461"
num_52WeekHigh="31.58"
num_52WeekLow="2.71"
num_50DayMovingAverage="4.446"
num_200DayMovingAverage="7.97"
SharesOutstanding="98384000"
DividendDate="None"
ExDividendDate="None"
symbol="FATE"
open="2.78"
high="2.78"
low="2.66"
price="2.73"
volume="1482671.00"
latest_trading_day="2023-08-21"
previous_close="2.78"
change="-0.05"
change_percent="-1.7986%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="98"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Trending High"
value_analysis="Bullish Trend"
Aroon_change="FALSE"
Aroon_momentum="2"
Volume_recent_avg="2253157"
Change_recent_avg="-0.03"
Delta_recent_avg="0.32"
Variance_recent_avg="0.16"
Change_ratio_recent_avg="-0.84"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="2"
Aroon_momentum_negative="98"
image_negative_thumbnail_id_1="496"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0109.jpeg"
image_negative_thumbnail_id_2="1104"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0137.jpeg"
image_neutral_thumbnail_id_1="552"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0047.jpeg"
image_neutral_thumbnail_id_2="590"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0009.jpeg"
image_positive_thumbnail_id_1="619"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0089.jpeg"
image_positive_thumbnail_id_2="609"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0099.jpeg"
image_professor_thumbnail_id_1="1184"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
image_professor_thumbnail_id_2="1189"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
